Media & Advertising
7/13/13 - Genentech Secures FDA Priority Review for Perjeta Regimen Prior to Surgery
Have an interest in this Story?
Sign Up for Real-Time email updates
July 13, 2013
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stag...
Read Full Article
Leave a Comment:
You must be logged in to leave a comment
Most Read Biotech Articles
Upcoming Conferences and Events, Technical Updates, and Dividends - Research Reports
- Ein News
Fitch Ratings Maintains Ecopetrol S.A.'s International and Local Ratings
REG-Starbreeze AB announces intent to acquire Geminose Inc. and sets up North American
bestwebdesignagencies.com Names the Fifty Best iPhone Development Companies for
Etrion and Hitachi High-Tech Announce Closing of Project Financing to Build 34 MW
Senior Vice President
View more profiles
Access dozens of premium and subscriptions sites
Build a News Circle
Get News Briefings
Congoo News Home
Get the Netpass
Copyright ©2014 Congoo.com. All Rights Reserved.